Jasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study
Jasper Therapeutics (JSPR) said Tuesday that Health Canada has cleared its clinical trial application for a phase 1b/2a asthma challenge study assessing briquilimab, an antibody therapy for mast cell-driven diseases.
The phase 1b/2a asthma study is expected to enroll 30 patients across 10 sites in Canada and the European Union, aiming to validate briquilimab's efficacy, with dosing beginning in Q4 and results expected in H2 2025, the company said.
The biotechnology company also said its c-Kit Mouse model has received a registered trademark from the US Patent and Trademark Office for its ability to test c-Kit or CD117 inhibitors in various diseases.
Price: 18.92, Change: -0.38, Percent Change: -1.97
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。